{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:03:55Z","timestamp":1792325035971,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10072-023-06676-1","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T20:08:47Z","timestamp":1676318927000},"page":"1841-1848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-386X","authenticated-orcid":false,"given":"Sohyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-5355","authenticated-orcid":false,"given":"Hung Youl","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"6676_CR1","unstructured":"Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. Internet (2022) Who.int. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/herd-immunity-lockdowns-and-covid-19. Accessed 11 Jul 2022"},{"key":"6676_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"6676_CR3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","volume":"22","author":"HG Rosenblum","year":"2022","unstructured":"Rosenblum HG, Gee J, Liu R et al (2022) Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect Dis 22:802\u2013812. https:\/\/doi.org\/10.1016\/S1473-3099(22)00054-8","journal-title":"Lancet Infect Dis"},{"key":"6676_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384:2187\u20132201. https:\/\/doi.org\/10.1056\/NEJMoa2101544","journal-title":"N Engl J Med"},{"key":"6676_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED, Kitchin N et al (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385:1761\u20131773. https:\/\/doi.org\/10.1056\/NEJMoa2110345","journal-title":"N Engl J Med"},{"key":"6676_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"6676_CR7","doi-asserted-by":"publisher","first-page":"871276","DOI":"10.3389\/fimmu.2022.871276","volume":"13","author":"M MacDougall","year":"2022","unstructured":"MacDougall M, El-Hajj Sleiman J, Beauchemin P, Rangachari M (2022) SARS-CoV-2 and multiple sclerosis: potential for disease exacerbation. Front Immunol 13:871276. https:\/\/doi.org\/10.3389\/fimmu.2022.871276","journal-title":"Front Immunol"},{"key":"6676_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5195\/ijms.2022.1241","volume":"10","author":"M Topolski","year":"2022","unstructured":"Topolski M, Soti V (2022) Effects of COVID-19 on multiple sclerosis relapse: a comprehensive review. Int J Med Stud 10:192\u2013201. https:\/\/doi.org\/10.5195\/ijms.2022.1241","journal-title":"Int J Med Stud"},{"key":"6676_CR9","doi-asserted-by":"publisher","unstructured":"Arrambide G, Llaneza-Gonz\u00e1lez M\u00c1, Costa-Frossard Fran\u00e7a L, Meca-Lallana V, D\u00edaz EF, Moreno-Torres I, Garc\u00eda-Dom\u00ednguez JM, Ortega-Suero G, Ayuso-Peralta L, G\u00f3mez-Moreno M, Sotoca-Fern\u00e1ndez JJ, Caminero-Rodr\u00edguez AB, Rodr\u00edguez de Antonio LA, Corujo-Su\u00e1rez M, Otano-Mart\u00ednez MA, P\u00e9rez-Miralles FC, Reyes-Garrido V, Ayuso-Blanco T, Balseiro-G\u00f3mez JJ, Mu\u00f1oz-Pasadas M, P\u00e9rez-Molina I, Arnal-Garc\u00eda C, Domingo-Santos \u00c1, Guijarro-Castro C, \u00cd\u00f1iguez-Mart\u00ednez C, T\u00e9llez Lara N, Castellanos-Pinedo F, Castillo-Trivi\u00f1o T, Cerd\u00e1n-Santacruz DM, P\u00e9rez-Sempere \u00c1, Torres BS, \u00c1lvarez de Arcaya A, Costa-Arp\u00edn E, Dur\u00e1n-Ferreras E, Fragoso-Mart\u00ednez M, Gonz\u00e1lez-Platas M, Landete Pascual L, Mill\u00e1n-Pascual J, Oreja-Guevara C, Meca-Lallana JE (2021) SARS-CoV-2 infection in multiple sclerosis: results of the spanish neurology society registry. Neurol Neuroimmunol Neuroinflamm 8(5):e1024. https:\/\/doi.org\/10.1212\/NXI.0000000000001024","DOI":"10.1212\/NXI.0000000000001024"},{"key":"6676_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s10072-021-05846-3","volume":"43","author":"M Hada","year":"2022","unstructured":"Hada M, Mosholder AD, Leishear K, Perez-Vilar S (2022) Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci 43:1557\u20131567. https:\/\/doi.org\/10.1007\/s10072-021-05846-3","journal-title":"Neurol Sci"},{"key":"6676_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77:1079\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2581","journal-title":"JAMA Neurol"},{"key":"6676_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780\u2013789. https:\/\/doi.org\/10.1002\/ana.26028","journal-title":"Ann Neurol"},{"key":"6676_CR13","unstructured":"COVID-19 vaccines for people who are moderately or severely immunocompromised. Internet (2022). Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html. Accessed 11 Jul 2022"},{"key":"6676_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jnnp-2021-327200","volume":"93","author":"M Di Filippo","year":"2022","unstructured":"Di Filippo M, Cordioli C, Malucchi S et al (2022) mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry 93:448\u2013450. https:\/\/doi.org\/10.1136\/jnnp-2021-327200","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"6676_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/vaccines10050763","volume":"10","author":"A Czarnowska","year":"2022","unstructured":"Czarnowska A, Tarasiuk J, Zajkowska O et al (2022) Safety of vaccines against SARS-CoV-2 among Polish patients with multiple sclerosis treated with disease-modifying therapies. Vaccines (Basel) 10(5):763. https:\/\/doi.org\/10.3390\/vaccines10050763","journal-title":"Vaccines (Basel)"},{"key":"6676_CR16","doi-asserted-by":"publisher","unstructured":"Stefanou MI, Palaiodimou L, Theodorou A, Christodoulou MV, Tzartos JS, Tzanetakos D, Kitsos D, Chondrogianni M, Zouvelou V, Dardiotis E, Tzavellas E, Syrigou E, Benetou V, Paraskevas GP, Tsiodras S, Tsivgoulis G, Giannopoulos S (2023) Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and metaanalysis. Mult Scler. https:\/\/doi.org\/10.1177\/13524585221150881","DOI":"10.1177\/13524585221150881"},{"key":"6676_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","volume":"19","author":"F Capone","year":"2022","unstructured":"Capone F, Lucchini M, Ferraro E et al (2022) Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics 19:325\u2013333. https:\/\/doi.org\/10.1007\/s13311-021-01165-9","journal-title":"Neurotherapeutics"},{"key":"6676_CR18","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Inglese M, Schiavetti I et al (2021) Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72:103581. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103581","journal-title":"EBioMedicine"},{"key":"6676_CR19","doi-asserted-by":"publisher","first-page":"103189","DOI":"10.1016\/j.msard.2021.103189","volume":"55","author":"I Lotan","year":"2021","unstructured":"Lotan I, Romanow G, Levy M (2021) Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Mult Scler Relat Disord 55:103189. https:\/\/doi.org\/10.1016\/j.msard.2021.103189","journal-title":"Mult Scler Relat Disord"},{"key":"6676_CR20","doi-asserted-by":"publisher","first-page":"103424","DOI":"10.1016\/j.msard.2021.103424","volume":"58","author":"A Dinoto","year":"2022","unstructured":"Dinoto A, Sechi E, Ferrari S et al (2022) Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Mult Scler Relat Disord 58:103424. https:\/\/doi.org\/10.1016\/j.msard.2021.103424","journal-title":"Mult Scler Relat Disord"},{"key":"6676_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"6676_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"6676_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J et al (2018) Association of Mog-IgG Serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG\u2013associated disorders. JAMA Neurol 75:1355\u20131363. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1814","journal-title":"JAMA Neurol"},{"key":"6676_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/jnnp-2021-326924","volume":"92","author":"M Butler","year":"2021","unstructured":"Butler M, Tamborska A, Wood GK et al (2021) Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. J Neurol Neurosurg Psychiatry 92:1144\u20131151. https:\/\/doi.org\/10.1136\/jnnp-2021-326924","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6676_CR25","doi-asserted-by":"publisher","first-page":"103739","DOI":"10.1016\/j.msard.2022.103739","volume":"60","author":"M Netravathi","year":"2022","unstructured":"Netravathi M, Dhamija K, Gupta M et al (2022) COVID-19 vaccine associated demyelination & its association with MOG antibody. Mult Scler Relat Disord 60:103739. https:\/\/doi.org\/10.1016\/j.msard.2022.103739","journal-title":"Mult Scler Relat Disord"},{"key":"6676_CR26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jama.2021.16496","volume":"326","author":"EJ Woo","year":"2021","unstructured":"Woo EJ, Mba-Jonas A, Dimova RB et al (2021) Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021. JAMA 326:1606\u20131613. https:\/\/doi.org\/10.1001\/jama.2021.16496","journal-title":"JAMA"},{"key":"6676_CR27","unstructured":"COVID-19 Vaccination. Internet (2022) Korea disease control and prevention agency. https:\/\/ncv.kdca.go.kr\/. Accessed 11 Jul 2022"},{"issue":"8","key":"6676_CR28","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/ene.15368","volume":"29","author":"M Rakusa","year":"2022","unstructured":"Rakusa M, \u00d6zt\u00fcrk S, Moro E et al (2022) COVID-19 vaccination hesitancy among people with chronic neurological disorders: a position paper. Eur J Neurol 29(8):2163\u20132172. https:\/\/doi.org\/10.1111\/ene.15368","journal-title":"Eur J Neurol"},{"key":"6676_CR29","doi-asserted-by":"publisher","first-page":"101494","DOI":"10.1016\/j.pmedr.2021.101494","volume":"24","author":"JD Allen","year":"2021","unstructured":"Allen JD, Feng W, Corlin L et al (2021) Why are some people reluctant to be vaccinated for COVID-19? A cross-sectional survey among U.S. Adults in May\u2013June 2020. Prev Med Rep 24:101494. https:\/\/doi.org\/10.1016\/j.pmedr.2021.101494","journal-title":"Prev Med Rep"},{"key":"6676_CR30","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.3346\/jkms.2023.38.e35","volume":"38","author":"S Kim","year":"2023","unstructured":"Kim S, Eun MY, Seok HY (2023) Letter to the Editor: consideration of neuroimmunological diseases in assessments of COVID-19 vaccination rates among patients with chronic medical conditions. J Korean Med Sci 38:e35. https:\/\/doi.org\/10.3346\/jkms.2023.38.e35","journal-title":"J Korean Med Sci"},{"key":"6676_CR31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.15585\/mmwr.mm7039a2","volume":"70","author":"AB Ryerson","year":"2021","unstructured":"Ryerson AB, Rice CE, Hung MC et al (2021) Disparities in COVID-19 vaccination status, intent, and perceived access for noninstitutionalized adults, by disability status - National immunization survey adult COVID module, United States, May 30\u2013June 26, 2021. MMWR Morb Mortal Wkly Rep 70:1365\u20131371. https:\/\/doi.org\/10.15585\/mmwr.mm7039a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6676_CR32","first-page":"281","volume":"8","author":"Y Hamed","year":"2021","unstructured":"Hamed Y, Abd Elaziz Shokry TM, Shehata KMA, Osman SM (2021) Could COVID-19 vaccine induce CNS demyelination. J Mult Scler 8:281","journal-title":"J Mult Scler"},{"key":"6676_CR33","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","volume":"362","author":"II Ismail","year":"2022","unstructured":"Ismail II, Salama S (2022) A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol 362:577765. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577765","journal-title":"J Neuroimmunol"},{"key":"6676_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00415-021-10780-7","volume":"269","author":"M Khayat-Khoei","year":"2022","unstructured":"Khayat-Khoei M, Bhattacharyya S, Katz J et al (2022) COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 269:1093\u20131106. https:\/\/doi.org\/10.1007\/s00415-021-10780-7","journal-title":"J Neurol"},{"key":"6676_CR35","doi-asserted-by":"publisher","unstructured":"M\u0103rginean CO, Meli\u021b LE, Cucuiet MT, Cucuiet M, Ra\u021biu M, S\u0103s\u0103ran MO (2022) COVID-19 Vaccine-A potential trigger for MOGAD transverse myelitis in a Teenager-A case report and a review of the literature. Children (Basel) 9(5):674. https:\/\/doi.org\/10.3390\/children9050674","DOI":"10.3390\/children9050674"},{"key":"6676_CR36","doi-asserted-by":"publisher","first-page":"845755","DOI":"10.3389\/fneur.2022.845755","volume":"13","author":"Y Matsumoto","year":"2022","unstructured":"Matsumoto Y, Ohyama A, Kubota T et al (2022) MOG antibody-associated disorders following SARS-CoV-2 vaccination: a case report and literature review. Front Neurol 13:845755. https:\/\/doi.org\/10.3389\/fneur.2022.845755","journal-title":"Front Neurol"},{"key":"6676_CR37","unstructured":"Society NMS (2022) COVID-19 Vaccine guidance for people living with MS. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/covid-19-vaccine-guidance. Accessed 29 Aug 2022"},{"key":"6676_CR38","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak P, Kim W, Paley MA et al (2021) Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med 174:1572\u20131585. https:\/\/doi.org\/10.7326\/M21-1757","journal-title":"Ann Intern Med"},{"key":"6676_CR39","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"key":"6676_CR40","doi-asserted-by":"publisher","first-page":"103394","DOI":"10.1016\/j.msard.2021.103394","volume":"58","author":"H Cai","year":"2022","unstructured":"Cai H, Zhou R, Jiang F, Zeng Q, Yang H (2022) Vaccination in neuromyelitis optica spectrum disorders: friend or enemy? Mult Scler Relat Disord 58:103394. https:\/\/doi.org\/10.1016\/j.msard.2021.103394","journal-title":"Mult Scler Relat Disord"},{"key":"6676_CR41","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06676-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06676-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06676-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T03:51:51Z","timestamp":1683863511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06676-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6676"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06676-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"17 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board of Keimyung University Dongsan Hospital approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by our institutional ethical board since the research involves no more than minimal risk to participants and does not adversely affect the rights and welfare of them.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}